Contact information
melanie.greenland@paediatrics.ox.ac.uk
https://orcid.org/0000-0001-9363-8844
Oxford Vaccine Group, CCVTM, Churchill Rd, Headington, Oxford, OX3 7LE
She/her
Research groups
Melanie Greenland
MSc BSc
Senior Medical Statistician & DPhil Student
Melanie is a Senior Medical Statistician and joined the Oxford Vaccine Group in 2020. She has experience of vaccine clinical trials in COVID-19, typhoid fever and pregnancy vaccine trials. She also has experience in women's reproductive health, obstetrics, neonatal, and cardiovascular research in clinical trials, linked electronic health data and Biobank data.
She was awarded a NIHR Doctoral Fellowship for her DPhil research into associations between reactogenicity following vaccination, immune responses and genetics.
Key publications
-
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Journal article
Liu X. et al, (2021), Lancet, 398, 856 - 869
-
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Journal article
Shaw RH. et al, (2021), Lancet, 397, 2043 - 2046
-
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article
Stuart ASV. et al, (2022), Lancet, 399, 36 - 49
Recent publications
-
Safety and immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin administered to pregnant women living with and without HIV and their newborns (WoMANPOWER): a randomised controlled trial in Uganda.
Journal article
Nakabembe E. et al, (2025), Lancet Glob Health, 13, e81 - e97
-
Clinical profile of paediatric acute rheumatic fever and rheumatic heart disease in Western Australia: 1987 to 2020.
Journal article
Kumar M. et al, (2024), J Paediatr Child Health